Results 71 to 80 of about 96,094 (164)

Interaction between Poly(ADP-ribose) polymerase-1 and α-synuclein pathology in Parkinson's disease. [PDF]

Front Neurosci
Zhang P, Li Q, Diao X, Zeng S.
europepmc   +1 more source

Synthetic lethality in cancer: mechanism exploration and therapeutic applications. [PDF]

Cell Commun Signal
Zhao P, Wang P, Xu T, Chen L, Jia Q, Li M.   +5 more
europepmc   +1 more source

New Insights into Parthanatos as Programmed Cell Death During Murine Cytomegalovirus or Herpes Simplex Virus Type 1 Productive Replication in Diverse Cell Types. [PDF]

Cells
Oh JJ, Xie X, Dix RD.
europepmc   +1 more source

PARylation-centric crosstalk: orchestrating immune evasion and multidrug resistance in ovarian cancer. [PDF]

Front Immunol
Hou L, Zhang M, Tong W, Zhang S.
europepmc   +1 more source

Advances in PARP Inhibition in Improving Outcomes of Breast Cancer, Ovarian Cancer, and Other Solid Tumors: Journey of Discovery, Development, and Clinical Updates of Talazoparib. [PDF]

Drug Des Devel Ther
Latif M, Mazhar S, Tasleem M, Alqurashi A, Arfan M, Ashraf Z, Zafar MS.   +6 more
europepmc   +1 more source

Glioblastoma and PARP inhibitors: the importance of patient selection to maximize therapeutic benefits. A critical review. [PDF]

Front Oncol
Dima G, Di Nunno V, Aprile M, Gatto L, Tosoni A, Argento CM, Margotti M, Bartolini S, Franceschi E.   +8 more
europepmc   +1 more source

RTA-408 induces JNK-dependent apoptosis and autophagy in breast cancer cells. [PDF]

Oncol Lett
Chen YJ, Tsai HP, Chen MY, Chen IH, Chen WC, Tseng TT, Wang CY, Lee JH.   +7 more
europepmc   +1 more source

The effect of PARP inhibitor-based targeted therapy on BRCA-mutated ovarian cancer: systematic literature review. [PDF]

Front Oncol
Panjarwanto DA, Nabila P, Octavia L, Indrawan IWA, Utomo RP, Permana AY, Kaspan, Adnyana IGHE, Javier RM, Akbar MZH.   +9 more
europepmc   +1 more source

Advancements in the manufacturing routes for the synthesis of marketed PARP inhibitors. [PDF]

RSC Adv
Rani D, Plebanski M, Chatterjee T.
europepmc   +1 more source

Advances in Phase III Clinical Trials and Future Challenges of Targeted Therapy in Advanced Ovarian Cancer. [PDF]

Cancer Manag Res
Zhang L, Qiao R, Chen M, Yang Z, Gong M, Yu R.   +5 more
europepmc   +1 more source